Toxicities Associated with Sacituzumab Govitecan

Data from multiple sources provide insights into the safety profile of #Sacituzumab #Govitecan (SG), identifying common hematologic toxicities and unexpected #AdverseEffects, underscoring the need for critical clinical monitoring & management.

Read: doi.org/10.1007/s115...

#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery